10 January 2018

Proud to be a DNDi partner

Proud to be among DNDi partners. DNDi and partners developed a breakthrough treatment for sleeping sickness

The first all-oral treatment for has been proven to be effective and safe, Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT) according to the results of clinical trials led by the Drugs for Neglected Diseases initiative (DNDi) and its partners, published in The Lancet and reported also in Nature.

As announced in a recent press release, DNDi aim was to deliver a safe, effective and orally administered drug to replace current first-line treatments, improving and facilitating current case management. Sleeping sickness, is usually fatal without treatment, is endemic to Africa and generally infects extremely poor people who live in remote regions. The sick often suffer from the disease for years before seeking treatment.

The oral therapy — called fexinidazole — cured 91.2% of people with severe sleeping sickness, compared with 97.6 who were treated with the combination therapy. It also cured 98.7% of people in an early stage of the disease. The relative ease of the treatment with fexinidazole might save more lives than the current options.

Accelera is proud to be among DNDi partners and of the contribution given to the development of this successful project.

If you would like to schedule a meeting to discuss potential collaborations with Accelera, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..